Jazz Pharmaceuticals JAZZ Proceeds from disposition of marketable securities and other investments
Proceeds from disposition of marketable securities and other investments at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's proceeds from disposition of marketable securities and other investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's proceeds from disposition of marketable securities and other investments?
- Jazz Pharmaceuticals (JAZZ) reported proceeds from disposition of marketable securities and other investments of $520M in Q1 2026.
- How has Jazz Pharmaceuticals's proceeds from disposition of marketable securities and other investments changed year-over-year?
- Jazz Pharmaceuticals's proceeds from disposition of marketable securities and other investments increased by 67.7% year-over-year, from $310M to $520M.
- What is the long-term trend for Jazz Pharmaceuticals's proceeds from disposition of marketable securities and other investments?
- Over 3 years (2022 to 2025), Jazz Pharmaceuticals's proceeds from disposition of marketable securities and other investments has grown at a 183.0% compound annual growth rate (CAGR), from $60M to $1.36B.